Trial · NCT02640664

Participant flow18

How many started, completed or left each group, period by period.

1 to 18 of 18

Period	Milestone	Group	Participants
Epoch 1	STARTED	Ranibizumab 0.2 mg	61
Epoch 1	STARTED	Ranibizumab 0.1 mg	65
Epoch 1	STARTED	Laser Therapy	54
Epoch 1	COMPLETED	Ranibizumab 0.2 mg	60
Epoch 1	COMPLETED	Ranibizumab 0.1 mg	65
Epoch 1	COMPLETED	Laser Therapy	53
Epoch 1	NOT COMPLETED	Ranibizumab 0.2 mg	1
Epoch 1	NOT COMPLETED	Ranibizumab 0.1 mg	0
Epoch 1	NOT COMPLETED	Laser Therapy	1
Epoch 2	STARTED	Ranibizumab 0.2 mg	60
Epoch 2	STARTED	Ranibizumab 0.1 mg	65
Epoch 2	STARTED	Laser Therapy	53
Epoch 2	COMPLETED	Ranibizumab 0.2 mg	54
Epoch 2	COMPLETED	Ranibizumab 0.1 mg	55
Epoch 2	COMPLETED	Laser Therapy	47
Epoch 2	NOT COMPLETED	Ranibizumab 0.2 mg	6
Epoch 2	NOT COMPLETED	Ranibizumab 0.1 mg	10
Epoch 2	NOT COMPLETED	Laser Therapy	6

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT02640664/flow